Multi-GWAS analysis illuminates druggable targets for rheumatoid arthritis.

Area of Science:

• Genetics
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) treatment options are expanding, yet significant unmet needs for prevention and therapy persist.
• Identifying novel drug targets is crucial for advancing RA management.

Purpose of the Study:

• To identify effective drug target genes for reducing rheumatoid arthritis (RA) risk using multi-genome-wide association studies (GWAS).
• To investigate the causal relationships between druggable genes, RA, and related autoimmune conditions.

Main Methods:

• Mendelian randomization (MR) analysis to assess causal effects of blood-based druggable expression quantitative trait loci (eQTLs) on RA.
• Colocalization analysis to identify shared causal variants between drug targets and RA.
• Single-cell eQTLs analysis in B and T cells, and Summary-data-based MR (SMR) for methylation levels.

Main Results:

• Five drug target genes (CCR6, CTLA4, EDN3, FCRL3, STAT4) were found to be causally associated with RA.
• Specific cell types (e.g., Th1/17, Th17, CD4 TFH, naive B cells) showed associations with CCR6, EDN3, and FCRL3 at single-cell resolution.
• SMR analysis linked multiple methylation probes of CCR6 and EDN3 to RA, with no significant side effects observed for the identified genes.

Conclusions:

• Five druggable genes represent promising therapeutic targets for rheumatoid arthritis.
• These findings provide critical insights for prioritizing future drug development strategies in RA.